Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Fenebrutinib blocks the function of BTK, an enzyme that regulates B-cell development and activation ... The candidate is a ...

Clinically, BTK inhibitors have shown remarkable efficacy in targeting malignant B-cells while sparing normal immune function to a considerable extent. Ongoing research continues to explore their ...

Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 ...

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has a path to market for a second after BTK inhibitor ... go-to therapy in B-cell non-Hodgkin ...

“These posters, as well as an additional focus on our assay development ... the combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies, PD biomarkers related ...

and small cell lymphocytic leukemia (SLL) indicates that the risk of adverse events is lower with a second-generation Bruton tyrosine kinase (BTK) inhibitor, compared to a first-generation ...

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene, will give the opening ceremony keynote, “Innovating for Impact: How ...